{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:32:25Z","timestamp":1788654745512,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.pnpbp.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T13:49:09Z","timestamp":1546523349000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Duloxetine plasma level and antidepressant response"],"prefix":"10.1016","volume":"92","author":[{"given":"Domenico","family":"De Donatis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Florio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-8759","authenticated-orcid":false,"given":"Stefano","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alois","family":"Saria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mercolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4363-3759","authenticated-orcid":false,"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2019.01.001_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"Association, A.P","year":"2000"},{"key":"10.1016\/j.pnpbp.2019.01.001_bb0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroimage.2013.10.002","article-title":"Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET","volume":"88","author":"Baldinger","year":"2014","journal-title":"NeuroImage"},{"key":"10.1016\/j.pnpbp.2019.01.001_bb0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jad.2015.09.033","article-title":"Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study","volume":"189","author":"Balestri","year":"2016","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.pnpbp.2019.01.001_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/15622970701227829","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for Biological Treatment of Unipolar Depressive Disorders in primary Care","volume":"8","author":"Bauer","year":"2007","journal-title":"World J. Biol. Psychiat."},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00213-006-0505-1","article-title":"Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder","volume":"188","author":"Bech","year":"2006","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pnpbp.2019.01.001_bb0030","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4088\/JCP.09m05723blu","article-title":"Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial","volume":"72","author":"Brecht","year":"2011","journal-title":"J. Clin. Psychiat."},{"issue":"6","key":"10.1016\/j.pnpbp.2019.01.001_bb0035","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2019.01.001_bb0040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/026988110201600413","article-title":"Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients","volume":"16","author":"Charlier","year":"2002","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2019.01.001_bb0045","first-page":"461","article-title":"Antidepressants might work for people with major depression: where do we go from here? The lancet","volume":"5","author":"Cipriani","year":"2018","journal-title":"Psychiatry"},{"issue":"9","key":"10.1016\/j.pnpbp.2019.01.001_bb0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00228-004-0810-8","article-title":"Are we going to increase the use of antidepressants up to that of benzodiazepines?","volume":"60","author":"Ciuna","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2019.01.001_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2019.01.001_bb0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4088\/JCP.v63n0407","article-title":"Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial","volume":"63","author":"Detke","year":"2002","journal-title":"J. Clin. Psychiat."},{"issue":"6","key":"10.1016\/j.pnpbp.2019.01.001_bb0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","article-title":"Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"14","author":"Detke","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2019.01.001_bb0070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000477770","article-title":"Dose Escalation of Antidepressants in Unipolar Depression: a Meta-Analysis of Double-blind, Randomized Controlled Trials","volume":"86","author":"Dold","year":"2017","journal-title":"Psychother. Psychosom."},{"issue":"1","key":"10.1016\/j.pnpbp.2019.01.001_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622975.2016.1208843","article-title":"Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response","volume":"18","author":"Fabbri","year":"2017","journal-title":"World J. Biol. Psychiat."},{"issue":"9","key":"10.1016\/j.pnpbp.2019.01.001_bb0080","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.euroneuro.2017.06.009","article-title":"Escitalopram plasma levels and antidepressant response","volume":"27","author":"Florio","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2019.01.001_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-2008-1073173","article-title":"The influence of smoking on the serum level of duloxetine","volume":"41","author":"Fric","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"7705","key":"10.1016\/j.pnpbp.2019.01.001_bb0090","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(71)92444-5","article-title":"Value of plasma-lithium monitoring","volume":"1","author":"Fry","year":"1971","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pnpbp.2019.01.001_bb0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-003-0710-3","article-title":"Time course of clinical response to venlafaxine: relevance of plasma level and chirality","volume":"59","author":"Gex-Fabry","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2019.01.001_bb0100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated","volume":"151","author":"Gillman","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4088\/JCP.v63n0309","article-title":"Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial","volume":"63","author":"Goldstein","year":"2002","journal-title":"J. Clin. Psychiat."},{"issue":"4","key":"10.1016\/j.pnpbp.2019.01.001_bb0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br. J. Social Clin. Psychol."},{"issue":"2","key":"10.1016\/j.pnpbp.2019.01.001_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S204579601700066X","article-title":"How do drugs for psychiatric disorders work?","volume":"27","author":"Harmer","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"1\u221202","key":"10.1016\/j.pnpbp.2019.01.001_bb0120","article-title":"Consensus guidelines for Therapeutic Drug monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2019.01.001_bb0125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1176\/appi.ajp.2015.15030331","article-title":"Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder","volume":"173","author":"Jakubovski","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/YIC.0b013e32832a8ec8","article-title":"Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram","volume":"24","author":"Kasper","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2019.01.001_bb0135","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4088\/JCP.v69n0905","article-title":"A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy","volume":"69","author":"Kornstein","year":"2008","journal-title":"J. Clin. Psychiat."},{"issue":"13","key":"10.1016\/j.pnpbp.2019.01.001_bb0140","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.bmcl.2004.04.066","article-title":"Synthesis and biological activity of some known and putative duloxetine metabolites","volume":"14","author":"Kuo","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pnpbp.2019.01.001_bb0145","article-title":"Multidimensional imaging techniques for prediction of treatment response in major depressive disorder","author":"Langenecker","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2019.01.001_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0165-0327(99)00147-0","article-title":"The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared","volume":"59","author":"Lawrenson","year":"2000","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0155","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200847030-00005","article-title":"In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine","volume":"47","author":"Lobo","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2019.01.001_bb0160","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jchromb.2007.05.046","article-title":"Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection. Journal of chromatography","volume":"856","author":"Mandrioli","year":"2007","journal-title":"Anal. Technol. Biomed. Life Sci."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2019.01.001_bb0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2007.05.031","article-title":"HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure. Journal of chromatography","volume":"856","author":"Mercolini","year":"2007","journal-title":"Anal. Technol. Biomed. Life Sci."},{"issue":"1","key":"10.1016\/j.pnpbp.2019.01.001_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jssc.200900493","article-title":"Simultaneous HPLC determination of 14 tricyclic antidepressants and metabolites in human plasma","volume":"33","author":"Mercolini","year":"2010","journal-title":"J. Sep. Sci."},{"issue":"5","key":"10.1016\/j.pnpbp.2019.01.001_bb0175","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study","volume":"161","author":"Meyer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2019.01.001_bb0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BFb0067700","article-title":"The Levenberg-Marquardt algorithm: Implementation and theory","volume":"630","author":"Mor\u00e9","year":"1977","journal-title":"Lecture Notes Mathem."},{"issue":"12","key":"10.1016\/j.pnpbp.2019.01.001_bb0185","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/ijnp\/pyx069","article-title":"Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2","volume":"20","author":"Moriguchi","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2019.01.001_bb0190","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jad.2017.11.004","article-title":"Early improvement and response to antidepressant medications in adults with major depressive disorder: Meta-analysis and study of a sample with treatment-resistant depression","volume":"227","author":"Olgiati","year":"2018","journal-title":"J. Affect. Disorders"},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JCP.0b013e318218f503","article-title":"Association between citalopram serum levels and clinical improvement of patients with major depression","volume":"31","author":"Ostad Haji","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2019.01.001_bb0200","doi-asserted-by":"crossref","first-page":"439","DOI":"10.31887\/DCNS.2008.10.4\/gipapakostas","article-title":"Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder","volume":"10","author":"Papakostas","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2019.01.001_bb0205","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pnpbp.2018.04.014","article-title":"Reduced clearance of venlafaxine in a combined treatment with quetiapine","volume":"85","author":"Paulzen","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2019.01.001_bb0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1368-5031.2006.00956.x","article-title":"Duloxetine 60 mg once daily in the treatment of milder major depressive disorder","volume":"60","author":"Perahia","year":"2006","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"10.1016\/j.pnpbp.2019.01.001_bb0215","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00004714-199408000-00002","article-title":"Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response","volume":"14","author":"Perry","year":"1994","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2019.01.001_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2005.09.022","article-title":"Therapeutic drug monitoring assay development to improve efficacy and safety","volume":"68","author":"Pippenger","year":"2006","journal-title":"Epilepsy Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2019.01.001_bb0225","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1517\/17425255.2011.597740","article-title":"Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism","volume":"7","author":"Porcelli","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.pnpbp.2019.01.001_bb0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00007691-200004000-00001","article-title":"Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?","volume":"22","author":"Rasmussen","year":"2000","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.pnpbp.2019.01.001_bb0235","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v58n0206d","article-title":"SSRI optimal dose remains at issue","volume":"58","author":"Rifkin","year":"1997","journal-title":"J. Clin. Psychiat."},{"issue":"5","key":"10.1016\/j.pnpbp.2019.01.001_bb0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hup.2544","article-title":"Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation","volume":"31","author":"Rovera","year":"2016","journal-title":"Human Psychopharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2019.01.001_bb0245","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00216-007-1320-1","article-title":"Current role of LC-MS in therapeutic drug monitoring","volume":"388","author":"Saint-Marcoux","year":"2007","journal-title":"Anal. Bioanal. Chem."},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0250","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","article-title":"TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians","volume":"19","author":"Schoretsanitis","year":"2018","journal-title":"World J. Biol. Psychiat."},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0255","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00213-010-1824-9","article-title":"Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2","volume":"210","author":"Sekine","year":"2010","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pnpbp.2019.01.001_bb0260","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0b013e3182228619","article-title":"Switching antidepressant class does not improve response or remission in treatment-resistant depression","volume":"31","author":"Souery","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2019.01.001_bb0265","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectrums"},{"issue":"4\u20135","key":"10.1016\/j.pnpbp.2019.01.001_bb0270","first-page":"174","article-title":"Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring","volume":"47","author":"Stamm","year":"2014","journal-title":"Pharmacopsychiatry"},{"issue":"Pt B","key":"10.1016\/j.pnpbp.2019.01.001_bb0275","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pnpbp.2017.07.006","article-title":"Patients with major depressive disorder exhibit reduced reward size coding in the striatum","volume":"79","author":"Takamura","year":"2017","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiat."},{"issue":"3","key":"10.1016\/j.pnpbp.2019.01.001_bb0280","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00213-005-0304-0","article-title":"A dose-finding study of duloxetine based on serotonin transporter occupancy","volume":"185","author":"Takano","year":"2006","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pnpbp.2019.01.001_bb0285","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/0269881109104863","article-title":"Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels","volume":"24","author":"Volonteri","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2019.01.001_bb0290","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/FTD.0b013e31815d0dfa","article-title":"Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching","volume":"29","author":"Waldschmitt","year":"2007","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.pnpbp.2019.01.001_bb0295","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0029-1220890","article-title":"Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey","volume":"42","author":"Waldschmitt","year":"2009","journal-title":"Pharmacopsychiatry"},{"issue":"Pt C","key":"10.1016\/j.pnpbp.2019.01.001_bb0300","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pnpbp.2017.04.026","article-title":"Effect of antidepressant treatment on peripheral inflammation markers - a meta-analysis","volume":"80","author":"Wiedlocha","year":"2018","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiat."},{"key":"10.1016\/j.pnpbp.2019.01.001_bb0305","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-0348-8183-8_5","article-title":"Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?","volume":"58","author":"Wong","year":"2002","journal-title":"Prog. Drug Res."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618308856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618308856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:46:26Z","timestamp":1759520786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584618308856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":61,"alternative-id":["S0278584618308856"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2019.01.001","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duloxetine plasma level and antidepressant response","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}